India
Industry
BMI View: Clinical research organisations (CROs) will increasingly penetrate India's clinical trial sector. Robust economic expansion and relative political stability will support development...
2011-12-02Industry
BMI View: India's pharmaceutical pricing policy is unusually transparent for an emerging market. It also admirably attempts to balance the requirements of the key stakeholders: patients,...
2011-11-11Industry
BMI View: India's healthcare market has strong fundamentals but is constrained by minimal government support, poor oversight, limited foreign investment and a cultural preference for...
2011-11-01Companies
BMI View: India's pharmaceutical market will increasingly attract foreign drugmakers. The government has made a clear statement that it values the contribution of multinationals to...
2011-10-13Industry
BMI View: GlaxoSmithKline (GSK) will acquire and Indian pharmaceutical company or select local medicine brands very shortly, despite the high premiums on these assets. We also believe...
2011-09-28Industry
BMI View: The regulatory environment of India's pharmaceutical market is far below international standards. Rules are poorly designed and implemented improperly. Our key concerns are...
2011-09-19Industry
BMI View: Growth in the number of mobile phone users and wireless subscribers and advances in the innovative application of communication technology has the potential to transform the...
2011-09-05Industry
BMI View: India's pharmaceutical market has entered a brief period of relative deterioration, primarily due to the country's economic slowdown and high inflation, which have negatively...
2011-09-02
